|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity显示文摘 | Perik PJ Rikhof B de Jong FA | 2008 | Ann Oncol2008，19，2： | 1 |
| 2 | The role of phosphatidylserine in recognition and removal of erythrocytes显示文摘 | Kuypers FA de Jong K | 2004 | Cell Mol Biol2004，50，2： | 1 |
| 3 | Non-isletcell tumor induced hypoglycemia in patients With advanced gastrointestinal stromal tumor possibly worsened by imatinih 显示文摘 | HAMBERG P de JONG FA BOONSTRA JG | 2006 | J Clin Oncol2006，24，18： | 1 |
| 4 | Subcellular localization of the bcl-2 protein in malignant and normal lymphoid cells 显示文摘 | Prins FA Mason DY | 1994 | Cancer Res1994，54，1： | 1 |
| 5 | Endoanal MRI of perianal fistulas:the optimal imaging planes显示文摘 | Jong TJien Fa VE EiJkemans MJC | 1998 | Eur Radiol1998，9，7： | 1 |
| 6 | Irinotec an-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein 显示文摘 | de JONG FA SCOTT-HORTON TJ KROETZ DL | 2007 | Clin Pharmacol Ther2007，81，1： | 1 |
| 7 | Chemical-induced apoptotic cell death in tomato cells involvement of caspase-like proteases显示文摘 | De Jong AJ Hoeberichts FA Yakimova E | 2000 | Planta2000，211，： | 1 |
| 8 | Prediction of irinotecan pharmacokinetics by use of cytochreme 17450 3A4 phenotyping probes显示文摘 | MATHIJSSEN RH JONG FA SCHAIK RH | 2004 | J Natl Cancer Inst2004，96，21： | 1 |
| 9 | ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition 显示文摘 | DE JONG FA MARSH S MATHIJSSEN RH | 2004 | Clin Cancer Res2004，10，17： | 1 |
| 10 | Flat-fixed dosing versusbody surface area based dosing of anticancer drugs in adults:does itmake a difference?显示文摘 | Mathijssen RH de Jong FA Loos WJ | 2007 | Oncologist2007，12，8： | 1 |
| 11 | Role of imatinib mesylate (Gleevec/ Glivec) in gastrointestinal stromal tumors显示文摘 | de Jong FA Verweij J | 2003 | J Expert Rev Anticancer Ther2003，3，6： | 1 |
| 12 | The role of phosphatidylserine in recogni- tion and removal of erythrocytes 显示文摘 | Kuypers FA de Jong K | 2004 | Cell Mol Biol (Noisy- le-grand)2004，50，2： | 1 |
| 13 | Flatfixed dosing of irinotecan , influence on pharrnacokinetic and pharmacodynamic variability显示文摘 | de Jong FA Mathijssen RH Xie R | 2004 | Clin Cancer Res2004，10，121： | 1 |
| 14 | Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes 显示文摘 | Mathijssen RH de Jong FA van Schaik RH Lepper ER Friberg LE Rietveld T | 2004 | J Natl Cancer Inst2004，96，21： | 1 |
| 15 | Biologic and clinical activity of tivozanib (AV- 951, KRN - 951), a selective inhibitor of VEGF receptor- 1, - 2, - 3 tyrosine kinascs, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors显示文摘 | ESKENS FA de JONGE M J BHARGAVA P | 2011 | Clin Cancer Res2011，17，22： | 1 |
| 16 | Hepatocellular car- cinoma: Dutch guideline for surveillance, diagnosis and therapy 显示文摘 | Eskens FA Van Erpecum KJ De Jong KP | 2014 | Neth J Med2014，72，6： | 1 |
| 17 | Non-islet-cell tumor induced hypoglycemia in patients with advanced gastrointestinal stromal tumor possibly worsened by imatinib显示文摘 | Hamberg P de Jong FA Boonstra JG | 2006 | J Clin Oncol2006，24，18： | 1 |
| 18 | The role of phosphatidylserine in recognition and removal of erythrocytes 显示文摘 | Kuypers FA de Jong K | 2004 | Cell Mol Biol2004，50，2： | 1 |
| 19 | Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes显示文摘 | de Jong FA van Schaik RH | 2004 | J Natl Cancer Inst2004，96，21： | 1 |
| 20 | Phase I dose-escalation study of F60008,a novel apoptosis inducer,in patients with advanced solid tumours显示文摘 | Kitzen JJ de Jonge MJ Lamers CH Eskens FA vander Biessen D van Doom L | 2009 | Eur J Cancer2009，45，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员